1. Home
  2. ANPA vs IBIO Comparison

ANPA vs IBIO Comparison

Compare ANPA & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rich Sparkle Holdings Limited Ordinary Shares

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

N/A

Current Price

$1.16

Market Cap

47.0M

Sector

N/A

ML Signal

N/A

IBIO

iBio Inc.

N/A

Current Price

$0.72

Market Cap

52.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANPA
IBIO
Founded
2016
2008
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
52.8M
IPO Year
2024
2009

Fundamental Metrics

Financial Performance
Metric
ANPA
IBIO
Price
$1.16
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $5.69
AVG Volume (30 Days)
18.1K
★ 470.8K
Earning Date
09-30-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.14
$0.69
52 Week High
$180.64
$3.82

Technical Indicators

Market Signals
Indicator
ANPA
IBIO
Relative Strength Index (RSI) 26.46 37.52
Support Level N/A $0.71
Resistance Level $2.18 $0.85
Average True Range (ATR) 0.10 0.06
MACD 0.02 0.01
Stochastic Oscillator 11.34 15.62

Price Performance

Historical Comparison
ANPA
IBIO

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: